Literature DB >> 28400625

IBD: Oncostatin M promotes inflammation in IBD.

Hugh Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28400625     DOI： 10.1038/nrgastro.2017.47

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Authors:  Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie
Journal:  Nat Med       Date:  2017-04-03       Impact factor: 53.440
  1 in total
  2 in total

1.  Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.

Authors:  Yueying Chen; Hanyang Li; Qi Feng; Jun Shen
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

2.  miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease.

Authors:  Carlos Perez-Sanchez; Ariana Barbera Betancourt; Paul A Lyons; Zinan Zhang; Chenqu Suo; James C Lee; Eoin F McKinney; Louise K Modis; Christian Ellson; Kenneth G C Smith
Journal:  J Exp Med       Date:  2022-04-01       Impact factor: 14.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.